Gorgas Gregory D.
Known title: Pres, CEO, CFO, Treas & SecrCIK: 0001526251
Gorgas Gregory D.'s purchase track record
Gorgas Gregory D. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/11/2022 | ARTL | $10K | -25.6% | -20.4% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARTL | ▲ Buy | Open Market | 1,200 | $5K | 8/12/2022 | View on chart |
| ARTL | ▲ Buy | Open Market | 1,200 | $5K | 8/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ARTL Selected for First Company Presentation at BIO‑Europe 2026
Artelo Biosciences has been chosen to present at BIO‑Europe 2026. The company will discuss clinical progress and the potential of its FABP5 inhibitor platform. This event highlights growing interest in the drug candidate and may increase visibility among researchers and investors. The presentation is a milestone in the company's development timeline.
ARTL Selected for First Company Presentation at BIO‑Europe 2026. Artelo Biosciences has been chosen to present at BIO‑Europe 2026. The company will discuss clinical progress and the potential of its FABP5 inhibitor platform. This event highlights growing interest in the drug candidate and may increase visibility among researchers and investors. The presentation is a milestone in the company's development timeline.